Format

Send to

Choose Destination
Jpn J Clin Oncol. 2012 Feb;42(2):131-3. doi: 10.1093/jjco/hyr183. Epub 2011 Dec 13.

Phase II trial of preoperative chemotherapy with docetaxel, cisplatin and S-1 for T4 locally advanced gastric cancer.

Author information

1
Department of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan. fushida@staff.kanazawa-u.ac.jp

Abstract

The standard treatment for T4 locally advanced gastric cancer is gastrectomy with D2 lymph node dissection followed by adjuvant chemotherapy with S-1 for 12 months; however, prognostic outcome in Stage IIIb has been insufficient. It is expected that survival is improved by preoperative treatment with a triplet regimen of docetaxel, cisplatin and S-1 (divided DCS therapy). A multicenter Phase II study has been conducted to evaluate the safety and efficacy of two courses of preoperative chemotherapy followed by gastrectomy. Fifty-five patients are required for this study. The primary endpoint of the study is pathological response rate of primary lesions. Secondary endpoints are overall survival, disease-free survival, R0 resection rate and adverse events.

PMID:
22167664
PMCID:
PMC3268464
DOI:
10.1093/jjco/hyr183
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center